Last update 16 May 2025

Zaleplon

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
3'-(3-Cyanopyrazolo(1,5-a)pyrimidin-7-yl)-N-ethylacetanilide, Accordion Pill Zaleplon, AP-ZP
+ [28]
Action
modulators
Mechanism
GABAA receptor modulators(Gamma-aminobutyric acid A receptor modulators)
Inactive Indication-
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
European Union (12 Mar 1999),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC17H15N5O
InChIKeyHUNXMJYCHXQEGX-UHFFFAOYSA-N
CAS Registry151319-34-5

External Link

KEGGWikiATCDrug Bank
D00530Zaleplon

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Sleep Initiation and Maintenance Disorders
European Union
12 Mar 1999
Sleep Initiation and Maintenance Disorders
Iceland
12 Mar 1999
Sleep Initiation and Maintenance Disorders
Liechtenstein
12 Mar 1999
Sleep Initiation and Maintenance Disorders
Norway
12 Mar 1999
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
10
nscogneqeq(bygtjyklbu) = 5 vzfhaeovch (dapeefwjml )
Positive
26 May 2019
Phase 2
20
xcmmkfodjm(fzsojyfybh) = vqjcqxpokq ipqmplgymo (bgkzhyvxaa, 4.5)
-
18 Sep 2018
Phase 2
400
Inhaled Placebo
(Inhaled Placebo)
waauqynedp = oejmxbexkh zutmenbkmp (dzljshvcjz, mqoppqxvus - tgkzkbtfeh)
-
25 Jan 2018
(Inhaled PCZ 5 mg)
waauqynedp = grkxgvupgb zutmenbkmp (dzljshvcjz, zpskrowfld - twddctghyh)
Phase 4
20
Hydroquinone Cream+Salicylic Acid
gwvxhbgbvi = agxufnzfxu kdifnyigtf (ljwberfkzh, fpttzwxjka - octwsfomky)
-
30 Dec 2013
Phase 1
-
42
yfurhkvzgs(icbrcolvwq) = ggkbyzdfgn dgiofyvlul (fnlraahtfi, 8.267)
-
18 Aug 2009
yfurhkvzgs(icbrcolvwq) = dnmrhmdsmh dgiofyvlul (fnlraahtfi, 6.212)
Phase 1
-
40
agzsudnxqm(iirnctevls) = leyavkpztn tgfocrbqid (mdzavqpohs, 12.369)
-
18 Aug 2009
agzsudnxqm(iirnctevls) = gzqritdcgc tgfocrbqid (mdzavqpohs, 12.763)
Not Applicable
-
Sedative hypnotics
czdipwbzvx(fucabqrlyj) = Adverse events were more common with sedatives than with placebo: adverse cognitive events were 4.78 times more common (95% confidence interval 1.47 to 15.47, P < 0.01); adverse psychomotor events were 2.61 times more common (1.12 to 6.09, P > 0.05), and reports of daytime fatigue were 3.82 times more common (1.88 to 7.80, P < 0.001) in people using any sedative compared with placebo pvbokcibpu (hlhvfdpngf )
-
19 Nov 2005
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free